TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02278341
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
Study: NCT00146289
Drug: MICARDIS® (telmisartan)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01773278
Drug: Antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
Study: NCT01773278
Drug: Cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
Study: NCT00162786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427960
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 5 mg
Study: NCT01956084
Drug: LMP1/2 CTLs (Group A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
Study: NCT01956084
Drug: LMP1/2 CTLs (Group B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
Study: NCT01200394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, placebo once daily for 12 weeks
Study: NCT02962947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily
Study: NCT01508156
Drug: IDX719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX719 liquid suspension (1 - 100 mg) taken by mouth.
Study: NCT01508156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid suspension matching IDX719 taken by mouth.
Study: NCT02525029
Drug: Pregnyl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.
Study: NCT02678897
Drug: Oxynorm via PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.
Study: NCT01337154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, orally, daily
Study: NCT01263899
Drug: SB1518
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
Study: NCT01678027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
Study: NCT01678027
Drug: LAC triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
Study: NCT00728052
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
Study: NCT00728052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be administered orally with water.
Study: NCT02902978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6130 matched placebo
Study: NCT00287079
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
Study: NCT04083339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
Study: NCT01539642
Drug: Sufentanil NanoTab PCA System/15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
Study: NCT01539642
Drug: Placebo Sufentanil NanoTab PCA System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
Study: NCT02751632
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
Study: NCT02751632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
Study: NCT02281630
Drug: KWA-0711
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02281630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03051646
Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
Study: NCT03051646
Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Study: NCT03311009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo provided as oral tablets q.d.
Study: NCT01743677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose placebo tablets (5 tablets)
Study: NCT02753218
Drug: LEO 32731
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03190369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Intra articular
Study: NCT00905216
Drug: heparin sodium - Bergamo
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.000 UI/mL
Study: NCT00905216
Drug: heparin sodium - APP
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.000 USP
Study: NCT02963831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
Study: NCT00409578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
Study: NCT02783885
Drug: immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02476422
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of diclofenac 50 mg soft gelatin capsule
Study: NCT02476422
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of ibuprofen 400 mg tablet
Study: NCT02476422
Drug: Placebo to ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo to ibuprofen 400 mg tablet
Study: NCT02476422
Drug: Placebo to diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
Study: NCT00138177
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00138177
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03120442
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.25 mcg fo Fentanyl for anxiolysis
Study: NCT02301611
Drug: TLPLDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor lysate, particle-loaded dendritic cell vaccine
Study: NCT02301611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00190554
Drug: Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03036306
Drug: SCX-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam cream formulation
Study: NCT00190554
Drug: (Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02947932
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: post-ERCP intervention in high risk patients
Study: NCT02291744
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
Study: NCT04147572
Drug: Placebo Spiriva capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation from HandiHaler
Study: NCT03715153
Drug: BUMETANIDE (S95008) for week 0 - 26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.
Study: NCT03715153
Drug: PLACEBO for week 0 - 26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution Taken twice daily.
Study: NCT03715153
Drug: Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.
Study: NCT01699854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03057509
Drug: Ga-68-DOTA-TOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
Study: NCT02876835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Study: NCT00076973
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 6 months
Study: NCT00003533
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04230681
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl
Study: NCT01545453
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous dose every 4 weeks
Study: NCT04233216
Drug: ISL
Normalized name: Dartisla
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISL 0.75 mg capsule taken by mouth.
Study: NCT04233216
Drug: Placebo to ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to ISL taken by mouth.
Study: NCT04233216
Drug: Placebo to DOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to DOR taken by mouth.
Study: NCT02617277
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 (adavosertib) is available in capsules for oral administration.
Study: NCT02617277
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 (durvalumab) will be administered by IV infusion.
Study: NCT03293927
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will receive IV fentanyl
Study: NCT01768962
Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application
Study: NCT01768962
Drug: Once Daily Application of TFV RG 1% gel - Rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal application
Study: NCT00583869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
Study: NCT00557427
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg - 40mg daily for 8 weeks
Study: NCT02483624
Drug: BR-DIM
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
Study: NCT02483624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02017639
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
Study: NCT01909427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injections (SC) every 4 weeks through Week 12
Study: NCT01909427
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
Study: NCT00718965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet in the evening with dinner
Study: NCT01078623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control twice daily
Study: NCT01690637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01431326
Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01358760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository
Study: NCT01298973
Drug: Viscoat
Normalized name: Viscoat
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group will receive Viscoat for incision closure
Study: NCT01257802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
Study: NCT02808871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 52 weeks
Study: NCT03161132
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 40mg/m2 every 28 days intravenous
Study: NCT03613662
Drug: SP-102
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT02794077
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
Study: NCT00115791
Drug: RSD1235
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00115791
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00932737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-5 tablets per episode
Study: NCT00932737
Drug: HBB 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug, one to five tablets per episode
Study: NCT04110587
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
Study: NCT04110587
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 4 mg I.V. (Intraoperative)
Study: NCT04110587
Drug: Antiinflammatories
Normalized name: ANTIINFLAMMATORY AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
Study: NCT04110587
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 575 mg / 8h by mouth (Post-operatively)
Study: NCT02176187
Drug: Berodual® Respimat® inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg
Study: NCT02176187
Drug: Berodual® metered dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg
Study: NCT03475693
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
Study: NCT03475693
Drug: Zofran ODT 4 MG Disintegrating Oral Tablet
Normalized name: Zofran ODT 4 MG Disintegrating Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given once in the Emergency department
Study: NCT03451942
Drug: FLOT regimen chemotherapy
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT regimen chemotherapy
Study: NCT00990938
Drug: IMO-2125
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
Study: NCT04349371
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
Study: NCT00971763
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00971763
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02655354
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-depressant
Study: NCT01703741
Drug: Testosterone Gel (FE 999093)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03350620
Drug: NVK-002 Concentration 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication will be administered, once daily (QD)
Study: NCT03350620
Drug: NVK-002 Concentration 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication will be administered, once daily (QD)
Study: NCT03350620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) will be administered, once daily (QD)
Study: NCT01515007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no